Weigh the bile acid standard and prepare it with methanol to make a final concentration of 1000 μg/mL mixed standard stock solution, then dilute the stock solution with 30% methanol, and dilute it to ten standard curve points. All stock solutions and working standard solutions were stored at -20℃.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS - alternating - reverse-phase"],"chromatography_protocol":["High speed bench refrigerated centrifuge was obtained from Hunan Xiangyi Experiment Equipment Co., Ltd. (Hunan, China). High throughput tissue grinder was obtained from Zhejiang Meibi Instrument Co., Ltd. (Zhejiang, China). Ultrasonic cleaner was obtained from Ningbo Xinzhi Biotechnology Co., Ltd. (Zhejiang, China). Multitube vortex mixer was obtained from Haimen Kylin-bell Lab Instruments Co., Ltd. (Haimen, China).
"],"publication":["Effects of Guanxinning tablet on the gut microbiota and bile acid metabolism in mice with hyperlipidemia."],"submitter_affiliation":["Zhejiang University of Technology"],"submitter_name":["B S"],"organism_part":["Cecal contents"],"technology_type":["mass spectrometry assay"],"disease":[""],"extraction_protocol":["Samples were extracted in 400 μL of methanol(-20℃)with two steel balls, vortex for 60 s. Put into a tissue grinder, grind at 55Hz for 1 min, and repeat the above operation at least twice. Sonicate for 30 min at room temperature, centrifuge at 12,000 rpm and 4℃ for 10 min, take 300 μL of the supernatant and add 600 μL of water to mix, and vortex for 30 s. Take an appropriate amount of supernatant and add 30% methanol to dilute 10 times. The supernatant was filtered through 0.22μm membrane, and the filtrate was added to the LC-MS bottle.
"],"organism":["Mus musculus"],"full_dataset_link":["https://www.ebi.ac.uk/metabolights/MTBLS14095"],"author":["Xincun Li. Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, China. 2008lixincun@163.com.","Chunsheng Zhu. Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, China. zhuchunsheng6@163.com."],"data_transformation_protocol":["Deoxycholic acid was obtained from Sigma-Aldrich (Shanghai, China). Dehydrocholic acid, Taurodeoxycholic acid Sodium Salt and Taurochenodeoxycholic acid were obtained from Macklin (Shanghai, China). Tauroursodeoxycholic Acid was obtained from National Institutes for Food and Drug Control (Beijing, China). Lithocholic acid, Chenodeoxycholic acid, Ursodeoxycholic acid, Cholic acid, Glycochenodeoxycholic acid Sodium Salt, Glycodeoxycholic acid Sodium Salt, Sodium Glycocholate Hydrate, Taurocholic acid Sodium Salt, Taurohyodeoxycholic Acid Sodium Salt were all obtained from Shyuanye (Shanghai, China).
"],"study_factor":["Treatment"],"submitter_email":["253313593@qq.com"],"sample_collection_protocol":["Freeze-dried samples, S.aureus was co-incubated with Ni-MOF in TSB medium at 37 ℃ with shaking at 230 rpm for 3 hours. After incubation, bacterial cells were harvested by centrifugation at 4000 rpm for 5 min at room temperature. The collected bacterial pellets were weighed, and only samples with a wet weight of ≥ 50 mg were retained for metabolomics analysis.
"],"omics_type":["Metabolomics"],"study_design":["FXR","hyperlipidemia","bile acids","gut microbiota","guanxinning tablet"],"curator_keywords":["FXR","hyperlipidemia","bile acids","guanxinning tablet","gut microbiota"],"mass_spectrometry_protocol":["High speed bench refrigerated centrifuge was obtained from Hunan Xiangyi Experiment Equipment Co., Ltd. (Hunan, China). High throughput tissue grinder was obtained from Zhejiang Meibi Instrument Co., Ltd. (Zhejiang, China). Ultrasonic cleaner was obtained from Ningbo Xinzhi Biotechnology Co., Ltd. (Zhejiang, China). Multitube vortex mixer was obtained from Haimen Kylin-bell Lab Instruments Co., Ltd. (Haimen, China).
"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Guanxinning tablet on the gut microbiota and bile acid metabolism in mice with hyperlipidemia","description":"Introduction: Guanxinning tablet (GXNT), a traditional Chinese medicine preparation, has been found to improve lipid metabolism in patients with cardiovascular disease. However, the underlying mechanisms are still poorly understood. This study aims to determine whether the gut microbiota and bile acid (BA) metabolism are involved in the mechanisms by which GXNT ameliorates hyperlipidemia.
Methods: The chemical composition of GXNT was characterized using UPLC-Q-TOF/MS. A mouse hyperlipidemia model was established through high-fat diet (HFD), and GXNT or simvastatin was administered by gavage for 6 weeks. The impact of GXNT on hyperlipidemia was assessed by measuring markers related to lipid metabolism, liver injury and inflammation. Furthermore, 16S rDNA sequencing, targeted metabolomics, immunohistochemistry, molecular docking and western blot were used to investigate the underlying mechanisms.
Results: GXNT treatment reduced blood lipid levels, improved liver injury, and mitigated hepatic inflammation in HFD-fed mice. GXNT also ameliorated the dysfunction of the intestinal barrier by upregulating the expression of zonula occludens-1 (ZO-1), occludin and claudin-1. Importantly, GXNT remodeled the gut microbiota in mice with hyperlipidemia, manifested by an increase in the abundance of Bacteroidota and Rikenellaceae_RC9_gut_group, as well as a decrease in the abundance of Desulfovibrio, Monoglobus, and Streptococcus. In addition, GXNT intervention altered the composition of fecal BAs and regulated BA metabolism by regulating the hepatic farnesoid X receptor (FXR)/small heterodimer partner (SHP) axis and intestinal FXR/fibroblast growth factor 15 (FGF15) axis.
Conclusions: GXNT improved hyperlipidemia in HFD-fed mice, which was associated with the gut microbiota and BA metabolism. Our results provide a theoretical basis for the application of GXNT.
","dates":{"publication":"2026-03-20","submission":"2026-03-20"},"accession":"MTBLS14095","cross_references":{}}